Datapoints
Search documents
Ginkgo Bioworks (DNA) - 2025 Q3 - Earnings Call Presentation
2025-11-06 21:30
Grow with Ginkgo Q3 2025 Update & Business Review November 6, 2025 Property of Ginkgo Bioworks — 1 Q2 2025 UPDATE & BUSINESS REVIEW Disclaimer FORWARD-LOOKING STATEMENTS This presentation, the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adaptations to meet our customers' needs, strategies, including with respect to our current expectations, operations a ...
Ginkgo Bioworks Announces Date of Third Quarter 2025 Results Presentation
Prnewswire· 2025-10-30 20:05
Core Points - Ginkgo Bioworks Holdings, Inc. plans to host a presentation and Q&A session on November 6, 2025, to review its business performance for Q3 2025 [1][2] - The presentation will be accessible via Ginkgo's investor relations website, and a replay will be available afterward [2] - Ginkgo Bioworks focuses on making biology easier to engineer, offering customizable R&D solutions, laboratory automation, and biosecurity technologies [3] Company Overview - Ginkgo Bioworks builds tools for biological engineering, providing R&D packages that include protein engineering and nucleic acid design [3] - The company also offers modular laboratory automation to enhance scientists' productivity [3] - Ginkgo Biosecurity is developing infrastructure to address biological threats globally [3]
Ginkgo Bioworks (DNA) - 2025 Q1 - Earnings Call Presentation
2025-05-07 01:07
Financial Performance & Targets - Ginkgo achieved $205 million in annual run-rate cost savings from Q1 2024 to Q1 2025[13] - The company maintains a strong financial position with $517 million in cash, cash equivalents, and marketable securities[15] - Total Adjusted EBITDA improved from $(117) million in Q1 2024 to $(47) million in Q1 2025, a 59% increase[34] - Ginkgo is targeting Adjusted EBITDA breakeven by the end of 2026[11, 49] - The company aims for $250 million of annualized run-rate savings target by the end of Q3 2025[53] Revenue & Growth - Cell Engineering revenue increased by 37% year-over-year, reaching $38 million in Q1 2025[34] - This includes recognition of $75 million non-cash deferred revenue from BiomEdit[24] - Total revenue increased by 27% year-over-year, from $38 million to $48 million[34] - Biosecurity revenue remained stable at $10 million in Q1 2025 compared to Q1 2024[34] Biosecurity Expansion - Ginkgo's biosecurity segment has expanded its reach to 127 countries of origin of flights sampled, representing 65% of nations globally[33] - The biosecurity network includes 11 key international airports and 45 collection nodes cumulatively in 2025[33]